Down syndrome: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• JAK 1
• G6PD 0
• PD-1 1

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)

  NCT06042257· Rachel G. Greenberg, MD, MB, MHS· Updated 17 Apr 2026

  “Study was stopped after careful review of product manufacturing needs and available resources. Decision reflects consideration of feasibility, enrollment challenges, and overall program goals.”Registry text, quoted unchanged. Source

• Terminated

  Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

  NCT06673069· Ionis Pharmaceuticals, Inc.· Updated 20 Feb 2026

  “Sponsor decision to terminate study early. Decision not based on safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study

  NCT02612376· University of Colorado, Denver· Updated 3 Jun 2025

  “Loss of funding”Registry text, quoted unchanged. Source

• Withdrawn

  Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

  NCT05482334· University of Colorado, Denver· Updated 2 Apr 2025

  “Difficulties enrolling participants due to study design”Registry text, quoted unchanged. Source

• Terminated

  LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

  NCT06860373· LuMind IDSC Foundation· Updated 6 Mar 2025

  “Unable to recruit”Registry text, quoted unchanged. Source

• Terminated

  Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome

  NCT04149197· LuMind IDSC Foundation· Updated 27 Jun 2024

  “COVID delayed study timelines. Competing studies began enrolling at our sites.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of ACI-24 in Adults With Down Syndrome

  NCT04373616· AC Immune SA· Updated 22 Oct 2021

  “decision to proceed with an optimized study design and optimized vaccine formulation”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  NCT03914625· National Cancer Institute (NCI)· Source

• A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT04546399· National Cancer Institute (NCI)· Source

• Effect of Sensory Integration on Gross and Balance on Children With Down Syndrome

  NCT07785011· Raheel Sanad· Source

• Harness-based Mobility Intervention for Infants With Down Syndrome

  NCT06219863· Boston University Charles River Campus· Source

• Evaluating Treatment of ADHD in Children With Down Syndrome

  NCT04219280· Children's Hospital Medical Center, Cincinnati· Source

• Executive Function Play Opportunities for Children With Down Syndrome

  NCT07792382· Colorado State University· Source

• Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without Thymectomy

  NCT07416201· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment

  NCT07643896· BillionToOne Inc.· Source

• A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

  NCT07636811· Alnylam Pharmaceuticals· Source

• Escalating Doses of Memantine in Down Syndrome (MEDS-123)

  NCT07531940· University Hospitals Cleveland Medical Center· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.